Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | MET | P08581 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12774647 | 0.81 | POLB (0.56) | ALDH1A1KMT2AMAPK1POLBGFER | |
| SCHEMBL2465209 | 0.81 | HTT (0.58) | ALDH1A1KMT2AMAPK1POLBGFER | |
| SCHEMBL2993237 | 0.81 | KMT2A (0.55) | ALDH1A1KMT2AMAPK1POLBGFER | |
| Hydrochloric Acid SCHEMBL7822738 | 0.80 | KMT2A (0.54) | ALDH1A1KMT2AMAPK1POLBGFER | |
| Ammonia Solution, Strong SCHEMBL21292105 | 0.80 | KMT2A (0.54) | ALDH1A1KMT2AMAPK1POLBGFER | |
| SCHEMBL13900945 | 0.79 | POLB (0.54) | ALDH1A1KMT2AMAPK1POLBGFER | |
| SCHEMBL15509416 | 0.77 | POLB (0.58) | ALDH1A1KMT2AMAPK1POLBGFER | |
| SCHEMBL16002834 | 0.77 | POLB (0.63) | ALDH1A1KMT2AMAPK1POLBGFER | |
| SCHEMBL14519922 | 0.77 | ALDH1A1 (0.53) | ALDH1A1KMT2AMAPK1POLBGFER | |
| SCHEMBL3803249 | 0.76 | ALDH1A1 (0.36) | ALDH1A1KMT2AMAPK1POLBGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339388-A1 | PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF | MAXYMUNE THERAPEUTICS INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250319046-A1 | PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF | MAXYMUNE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-12427124-B1 | Phenylalanine-based LAT1 inhibitors and uses thereof | Maxymune Therapeutics, Inc. (US) | 2025-09-30 | — | — | US | disclosed |
| US-12398141-B2 | JAK kinase inhibitor, preparation method for same, and applications thereof in field of medicine | SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO., LTD (CN) | 2025-08-26 | — | — | US | disclosed |
| US-20250250265-A1 | BENZOTHIAZOLE-PHENYLSULFONYL-PIPERIDINE ANALOGS AS ACTIVATORS OF NACYLPHOSPHATIDYLETHANOLAMINE HYDROLYZING PHOSPHOLIPASE D | VANDERBILT UNIVERSITY | 2025-08-07 | — | — | US | disclosed |
| CN-113631557-B | JAK kinase inhibitor, preparation method thereof and application thereof in medicine field | 上海华汇拓医药科技有限公司 | 2024-03-15 | — | — | CN | disclosed |
| WO-2023201014-A1 | BENZOTHIAZOLE-PHENYLSULFONYL-PIPERIDINE ANALOGS AS ACTIVATORS OF N-ACYLPHOSPHATIDYLETHANOLAMINE HYDROLYZING PHOSPHOLIPASE D | VANDERBILT UNIVERSITY (US) | 2023-10-19 | — | — | WO | disclosed |
| US-20220185816-A1 | JAK KINASE INHIBITOR, PREPARATION METHOD FOR SAME, AND APPLICATIONS THEREOF IN FIELD OF MEDICINE | SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO., LTD (CN) | 2022-06-16 | — | — | US | disclosed |
| EP-3939979-A1 | JAK KINASE INHIBITOR, PREPARATION METHOD FOR SAME, AND APPLICATIONS THEREOF IN FIELD OF MEDICINE | Shanghai Synergy Pharmaceutical Sciences Co., Ltd (CN) | 2022-01-19 | — | — | EP | disclosed |
| CN-113631557-A | JAK kinase inhibitor, preparation method thereof and application thereof in medical field | 上海华汇拓医药科技有限公司 | 2021-11-09 | — | — | CN | disclosed |
| WO-1997045403-A1 | ARYL SUBSTITUTED CYCLIC AMINES AS SELECTIVE DOPAMINE D3 LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 1997-12-04 | — | — | WO | disclosed |
| EP-0792873-A1 | N-(Phenoxyalkyl) carboxamides and their use as antiarrhythmic agents | American Cyanamid Company (US) | 1997-09-03 | — | — | EP | disclosed |
| US-5585397-A | VIRICIDES | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 1996-12-17 | — | — | US | disclosed |
| EP-0659181-A1 | SULFONAMIDE INHIBITORS OF HIV-ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1995-06-28 | — | — | EP | disclosed |
| WO-1994005639-A1 | SULFONAMIDE INHIBITORS OF HIV-ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1994-03-17 | — | — | WO | disclosed |
| EP-0404758-A1 | HERBICIDAL SULFONAMIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-01-02 | — | — | EP | disclosed |
| EP-0404758-A4 | HERBICIDAL SULFONAMIDES. | DU PONT (US) | 1989-08-30 | — | — | EP | disclosed |
| US-4854962-A | Herbicidal sulfonamides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-08-08 | — | — | US | disclosed |
| US-4746356-A | Herbicidal sulfonamides | E. I. DUPONT DE NEMOURS AND COMPANY (US) | 1988-05-24 | — | — | US | disclosed |
| WO-1987007114-A1 | HERBICIDAL SULFONAMIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250250265-A1 | BENZOTHIAZOLE-PHENYLSULFONYL-PIPERIDINE ANALOGS AS ACTIVATORS OF NACYLPHOSPHATIDYLETHANOLAMINE HYDROLYZING PHOSPHOLIPASE D | PLD1, PLD2, NAPEPLD | ALDH1A1 2820/4885KMT2A 1305/4885MAPK1 3420/4885 |
| US-20250339388-A1 | PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF | SLC43A1, SLC7A1, SLC1A5 | ALDH1A1 2745/4885KMT2A 3540/4885MAPK1 237/4885 |
| US-12427124-B1 | Phenylalanine-based LAT1 inhibitors and uses thereof | SLC43A1, SLC7A1, SLC1A5 | ALDH1A1 2745/4885KMT2A 3540/4885MAPK1 237/4885 |
| US-12398141-B2 | JAK kinase inhibitor, preparation method for same, and applications thereof in field of medicine | JAK1, JAK2, JAK3 | ALDH1A1 2619/4885KMT2A 460/4885MAPK1 158/4885 |
| US-20220185816-A1 | JAK KINASE INHIBITOR, PREPARATION METHOD FOR SAME, AND APPLICATIONS THEREOF IN FIELD OF MEDICINE | JAK1, JAK2, JAK3 | ALDH1A1 2619/4885KMT2A 460/4885MAPK1 158/4885 |
| US-20250319046-A1 | PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF | SLC43A1, SLC7A1, SLC1A5 | ALDH1A1 2745/4885KMT2A 3540/4885MAPK1 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.